PURPOSEDespite standardized surgical techniques, delayed gastric emptying (DGE) remains a major complication after Roux-en-Y reconstruction in gastric cancer patients. This study aimed to evaluate the efficacy of ω-3 fish oil fat emulsion in reducing DGE incidence and improving postoperative outcomes.METHODSIn this retrospective cohort study, 210 patients undergoing radical gastrectomy with Roux-en-Y reconstruction (Nanjing Drum Tower Hospital, 2018-2020) were stratified into two groups: the intervention group (n=139) received parenteral nutrition (PN) with ω-3 fish oil emulsion (0.2g/kg/day), while controls (n=71) received standard PN. DGE diagnosis required persistent symptoms (>72h postoperatively) and objective evidence of impaired motility (CT contrast retention ≥50% at 4h or scintigraphic T½ >90min), excluding mechanical obstructions (luminal stenosis <8mm).RESULTSThe ω-3 group exhibited significantly lower DGE incidence (4.3% vs. 15.5%, P=0.005) and shorter median postoperative hospital stay (10 vs. 13 days, P<0.001). Multivariate analysis identified ω-3 supplementation as an independent protective factor against DGE (OR=0.32, 95% CI:0.11-0.96, P=0.042). Symptom severity (Gastroparesis Cardinal Symptom Index) showed progressive improvement in the ω-3 cohort, with significant reductions in nausea and vomiting scores by week 4 (P<0.05).CONCLUSIONPerioperative ω-3 fish oil fat emulsion supplementation reduces DGE risk by 71%, accelerates recovery, and improves surgical outcomes in gastric cancer patients undergoing Roux-en-Y reconstruction. These findings support its integration into enhanced recovery protocols, particularly in high-risk populations.

01 Apr 2025·eBioMedicine

Prevalence, genetic variations and clinical outcomes of BRAF-V600 mutated advanced NSCLC in China: a retrospective real-world multi-centre study

Article

Author: Li, Yong ; Li, Jianjie ; Shi, Minmin ; Wang, Xi ; Yang, Xue ; Wang, Shuo ; Wang, Yuyan ; Jia, Bo ; Jiang, Caihong ; Zhang, Jiwei ; Li, Honglin ; Wang, Jingjing ; Jin, Bo ; Zhang, Fengyuan ; An, Tongtong ; Liu, Yiliang ; Chi, Yujia ; Lu, Lin ; Zhai, Xiaoyu ; Zhao, Jun ; Man, Li ; Shen, Fengqian ; Jin, Xin ; Wang, Ziping ; Wang, Zhen ; Wang, Yanlei ; Liu, Zhiliang ; Nuersulitan, Reyizha ; Zhuo, Minglei ; Zhang, Mengmeng ; Chen, Hanxiao ; Guan, Guohui ; Tai, Yidi ; Zhao, Yanbin ; Wang, Yudong ; Yan, Jingjing ; Liu, Xiuju

BACKGROUNDDue to the low incidence of BRAF mutations, limited data is available about their prevalence and clinical characteristics. Moreover, comparative real-world efficacy of dabrafenib combined with trametinib versus other treatment regimens, especially in Chinese patients, is also lacking.METHODSPatients who had BRAF genetic testing from the Lung Cancer Big Data Precise Treatment Collaboration Group (LANDSCAPE) database were included as Cohort I. The LANDSCAPE database comprises next-generation sequencing (NGS) data of 175,336 patients with lung cancer, originating from 6 Chinese genetic testing institutions. Cohort II included patients with unresectable locally advanced or metastatic NSCLC with a primary BRAF mutation from 19 centres in China from December 2015 to September 2022.FINDINGSIn Cohort I, of patients with NSCLC, 6249 (3.56%, 95% CI: 3.48%-3.65%) were confirmed to harbour a BRAF mutation. BRAF V600E accounted for 24.6% (1539/6249) of all patients with BRAF-mutated NSCLC. In Cohort II, a total of 129 patients with locally advanced or metastatic BRAF-mutated NSCLC were included. Of 112 patients who received NGS testing, 80 (71.4%) patients had concomitant mutations. The median first-line real-world progression-free survival (rwPFS) of dabrafenib plus trametinib for patients with BRAF V600 mutations was 25.0 months (N = 37), which was numerically longer than first-line immunotherapy-based therapy (N = 12, 15.7 months), and chemotherapy (N = 17, 9.2 months).INTERPRETATIONThis study indicates that dabrafenib plus trametinib could be considered as the optimal treatment option for Chinese patients with NSCLC harbouring BRAF V600 mutations.FUNDINGNational Natural Science Foundation of China (82072583); Beijing Municipal Administration of Hospitals Incubating Program (PX2020044); Beijing Hospitals Authority Youth Programme (QML20231113); Science Foundation of Peking University Cancer Hospital (2022-17); Peking University Cancer Hospital Inner Mongolia Hospital Public Hospital Reform and High-Quality Development Demonstration Project (Gastrointestinal Cancer + Thoracic Cancer) Research Fund (2024YNYB006).

28 Mar 2025·China CDC weekly

Current Status and Factors of Vaccine Hesitancy in Tetanus Vaccination Among Traumatic Patients - China, 2024.

Article

Author: Chen, Xuan ; Liu, Si ; Liu, Cheng ; Wang, Chuanlin ; Zhang, Mengjie ; Zheng, Xiangde ; Cai, Yufeng ; Xu, Yingjun ; Zhao, Yang ; Zuo, Liping ; Xue, Qiaosheng ; Tang, Yingli ; Wang, Zhijun

What is already known about this topic?The incidence of tetanus in China remains significantly higher than in economically developed regions. Tetanus vaccination represents the most scientifically validated and efficient approach to tetanus prevention. However, vaccine hesitancy presents substantial barriers to the widespread implementation of non-neonatal tetanus vaccination programs across China.What is added by this report?This study constitutes the first comprehensive investigation of tetanus vaccine hesitancy in China, documenting its current prevalence and underlying determinants. Findings reveal that limited knowledge about tetanus vaccines, complacency regarding tetanus risk, advanced age, and other factors significantly contribute to vaccination hesitancy. The research demonstrates that medical institutions and healthcare providers offering evidence-based information about tetanus prevention may substantially enhance vaccination uptake.What are the implications for public health practice?By elucidating the specific reasons for tetanus vaccine refusal among trauma patients, this study provides critical insights for government agencies and health policymakers to develop contextually appropriate interventions aligned with China's national circumstances, ultimately facilitating improved tetanus vaccination coverage.

100 Deals associated with Dezhou Municipal Hospital

100 Translational Medicine associated with Dezhou Municipal Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 30 Jun 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Dezhou Municipal Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 30 Jun 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing